Oh great, another stem cell moon shot.
NSI-566 is an experimental stem cell-based therapy that Seneca Biopharma (previously known as Neuralstem) is developing as a potential treatment for amyotrophic lateral sclerosis (ALS).
The company also is investigating NSI-566 as a potential treatment for chronic spinal cord injury and to restore motor deficits after an ischemic stroke or traumatic brain injury.
The U.S. Food and Drug Administration (FDA) granted NSI-566 orphan drug designation for the treatment of ALS in August 2018.
The latest here:
Seneca Biopharma, Inc. Announces Completion of Phase II Clinical Study in China for the Treatment of Ischemic Stroke
GERMANTOWN, Md., Sept. 10, 2020 /PRNewswire/ -- Seneca Biopharma, Inc. (Nasdaq: SNCA),
a biopharmaceutical company focused on developing novel treatments for
diseases of high unmet medical need, today announced that the last
subject completed their final follow-up assessment in the Company's
non-GCP Phase II study in Beijing, China
evaluating NSI-566 for the treatment of chronic ischemic stroke. With
this milestone achieved, the company remains on schedule to release top
line data for the study during the fourth quarter of 2020.
No comments:
Post a Comment